- Home
- SRV vs CCCC Comparison
SRV vs CCCC Comparison
Compare SRV & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- CCCC
- Stock Information
- Founded
- SRV 2007
- CCCC 2015
- Country
- SRV United States
- CCCC United States
- Employees
- SRV N/A
- CCCC N/A
- Industry
- SRV Finance Companies
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- SRV Finance
- CCCC Health Care
- Exchange
- SRV Nasdaq
- CCCC Nasdaq
- Market Cap
- SRV 193.1M
- CCCC 160.1M
- IPO Year
- SRV N/A
- CCCC 2020
- Fundamental
- Price
- SRV $41.94
- CCCC $2.48
- Analyst Decision
- SRV
- CCCC Strong Buy
- Analyst Count
- SRV 0
- CCCC 4
- Target Price
- SRV N/A
- CCCC $8.50
- AVG Volume (30 Days)
- SRV 33.9K
- CCCC 2.8M
- Earning Date
- SRV 01-01-0001
- CCCC 11-03-2025
- Dividend Yield
- SRV 13.38%
- CCCC N/A
- EPS Growth
- SRV N/A
- CCCC N/A
- EPS
- SRV N/A
- CCCC N/A
- Revenue
- SRV N/A
- CCCC $34,240,000.00
- Revenue This Year
- SRV N/A
- CCCC N/A
- Revenue Next Year
- SRV N/A
- CCCC N/A
- P/E Ratio
- SRV N/A
- CCCC N/A
- Revenue Growth
- SRV N/A
- CCCC 16.55
- 52 Week Low
- SRV $30.73
- CCCC $1.09
- 52 Week High
- SRV $44.30
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- SRV 30.37
- CCCC 52.98
- Support Level
- SRV $43.06
- CCCC $1.99
- Resistance Level
- SRV $44.67
- CCCC $2.50
- Average True Range (ATR)
- SRV 0.98
- CCCC 0.20
- MACD
- SRV -0.34
- CCCC 0.00
- Stochastic Oscillator
- SRV 1.68
- CCCC 59.04
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.